Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma
- 1 November 1987
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 25 (3) , 257-265
- https://doi.org/10.1007/bf00199156
Abstract
A total of 80 patients with melanoma metastases in regional lymph nodes were treated by i.d. injections with a vaccine prepared from a vaccinia virus-infected allogeneic melanoma cell line; 39 patients have been followed for a 2-year period. Interim results from comparison of the treated group with 151 historical controls treated without the vaccine from September 1978 to December 1981 at the same institution and 56 non-randomized concurrent controls suggest that survival was significantly prolonged in the vaccinated group. At the 2-year period overall survival was 75% in the treated compared to 57% in the historical control group. Subset analysis showed a greater apparent benefit of vaccine therapy among patients who had metastases detected at the time of treatment of the primary melanoma (synchronous metastases), while therapy appeared less effective in patients with metastases detected at some time after treatment of the primary (delayed metastases). In the latter only those with one lymph node appeared to benefit from the treatment whereas in patients with synchronous metastases patients with three or more nodes as well as one node appeared to have improved survival. The survival rates at 2 years for treated patients with synchronous metastases in one, two, three or more lymph nodes was 100%, 83% and 79% respectively compared with that of 82%, 86% and 47% respectively in the equivalent control groups. Survival rates in treated patients with delayed metastases in one, two, three or more lymph nodes was 70%, 70% and 65% compared with 47%, 42% and 35% in the equivalent control groups. Treatment and control groups appeared well matched for a number of known prognostic features, including number and size of involved nodes, sex and thickness of primary tumor. Multivariate analysis indicated the effect of treatment was independent of these factors. Despite the empiricism of this approach the present results suggest that this form of therapy warrants further evaluation in a randomized controlled trial.Keywords
This publication has 36 references indexed in Scilit:
- Review of melanoma antigens recognized by monoclonal antibodies (MAbs). their functional significance and applications in diagnosis and treatment of melanomaPathology, 1985
- CURRENT STATUS AND FUTURE PROSPECTS FOR ADJUVANT THERAPY OF MELANOMAAnz Journal of Surgery, 1984
- The augmentation of tumor‐specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus‐reactive helper T cellsEuropean Journal of Immunology, 1983
- Localization at high resolution of antibody-induced mobilization of vaccinia virus hemagglutinin and the major histocompatibility antigens on the plasma membrane of infected cells.The Journal of Experimental Medicine, 1982
- A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous MelanomaNew England Journal of Medicine, 1982
- GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.The Journal of Experimental Medicine, 1982
- Human malignant melanoma cell linesPathology, 1979
- A cytogenetic study of eight human melanoma cell linesPathology, 1979
- TREATMENT OF PRIMARY MELANOMA BY INTRALESIONAL VACCINIA BEFORE EXCISIONThe Lancet, 1975
- SOME METHODS USED IN THE MANAGEMENT OF METASTATIC MALIGNANT MELANOMAAustralasian Journal of Dermatology, 1963